Synthetic enzyme inhibitor: A novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 6, 2011, Pages 665-673

  Liao, Debbie ^a   Liu, Ze ^a,b   Wrasidlo, Wolfgang ^c   Chen, Tingmei ^a   Luo, Yunping ^a   Xiang, Rong ^a,b   Reisfeld, Ralph A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NANKAI UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cancer; Legumain; Ligand targeting; Liposome

Indexed keywords

ANIMAL MODEL; ANTITUMOR EFFECT; ASPARAGINYL; CANCER; CELL SURFACE EXPRESSION; DOXORUBICIN; DRUG SENSITIVITY; GENETIC HETEROGENEITIES; HYPOXIC STRESS; INHIBITING EFFECT; INHIBITION OF TUMOR GROWTH; LEGUMAIN; LIGAND-RECEPTOR; LIGAND-TARGETING; SOLID TUMORS; SYNTHETIC ENZYMES; TARGET RECEPTOR; TUMOR CELLS; TUMOR GROWTH;

BIOELECTRIC POTENTIALS; DRUG DELIVERY; ENZYMES; LIGANDS; LIPOSOMES; NANOPARTICLES; TOXICITY;

TUMORS;

DOXORUBICIN; ENZYME INHIBITOR; LEGUMAIN; LIGAND; NANOPARTICLE; RDZ 218; RHODAMINE B; RR 11A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL SURFACE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENCAPSULATION; ENZYME INHIBITION; FEMALE; HYPOXIA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR AFFINITY; SOLID TUMOR; TUMOR CELL; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYSTEINE ENDOPEPTIDASES; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; LIGANDS; LIPOSOMES; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASMS; PROTEASE INHIBITORS;

ANIMALIA; MUS;

EID: 82255191976     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.03.001     Document Type: Article

References (25)

1. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010, 188(6):759-768.
2. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991, 88(24):11460-11464.
3. Lotem M., Hubert A., Lyass O., Goldenhersh M.A., Ingber A., Peretz T., et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000, 136(12):1475-1480.
4. Lyass O., Uziely B., Ben-Yosef R., Tzemach D., Heshing N.I., Lotem M., et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89(5):1037-1047.
5. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2(12):751-760.
6. Ekici O.D., Gotz M.G., James K.E., Li Z.Z., Rukamp B.J., Asgian J.L., et al. Aza-peptide Michael acceptors: a new class of inhibitors specific for caspases and other clan CD cysteine proteases. J Med Chem 2004, 47(8):1889-1892.
7. Barrett A.J., Rawlings N.D. Evolutionary lines of cysteine peptidases. Biol Chem 2001, 382(5):727-733.
8. Murthy R.V., Arbman G., Gao J., Roodman G.D., Sun X.F. Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res 2005, 11(6):2293-2299.
9. Gawenda J., Traub F., Luck H.J., Kreipe H., von Wasielewski R. Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat 2007, 102(1):1-6.
10. Liu C., Sun C., Huang H., Janda K., Edgington T. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res 2003, 63(11):2957-2964.
11. Wu W., Luo Y., Sun C., Liu Y., Kuo P., Varga J., et al. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res 2006, 66(2):970-980.
12. Ekici O.D., Li Z.Z., Campbell A.J., James K.E., Asgian J.L., Mikolajczyk J., et al. Design, synthesis, and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3, -6, -7, -8, -9, and -10. J Med Chem 2006, 49(19):5728-5749.
13. Niestroj A.J., Feussner K., Heiser U., Dando P.M., Barrett A., Gerhartz B., et al. Inhibition of mammalian legumain by Michael acceptors and AzaAsn-halomethylketones. Biol Chem 2002, 383(7-8):1205-1214.
14. Ovat A., Muindi F., Fagan C., Brouner M., Hansell E., Dvorak J., et al. Aza-peptidyl Michael acceptor and epoxide inhibitors-potent and selective inhibitors of Schistosoma mansoni and Ixodes ricinus legumains (asparaginyl endopeptidases). J Med Chem 2009, 52(22):7192-7210.
15. Powers J.C., Asgian J.L., Ekici O.D., James K.E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev 2002, 102(12):4639-4750.
16. Gotz M.G., James K.E., Hansell E., Dvorak J., Seshaadri A., Sojka D., et al. Aza-peptidyl Michael acceptors. A new class of potent and selective inhibitors of asparaginyl endopeptidases (legumains) from evolutionarily diverse pathogens. J Med Chem 2008, 51(9):2816-2832.
17. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29(5):625-634.
18. Wang G.L., Semenza G.L. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 1993, 90(9):4304-4308.
19. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
20. Kuukasjarvi T., Karhu R., Tanner M., Kahkonen M., Schaffer A., Nupponen N., et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997, 57(8):1597-1604.
21. Liu Y., Miyoshi H., Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer 2007, 120(12):2527-2537.
22. Ferrari M. Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer 2005, 5(3):161-171.
23. Murphy E.A., Majeti B.K., Barnes L.A., Makale M., Weis S.M., Lutu-Fuga K., et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A 2008, 105(27):9343-9348.
24. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002, 2(10):750-763.
25. Muller I., Niethammer D., Bruchelt G. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review). Int J Mol Med 1998, 1(2):491-494.